Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate to severe plaque psoriasis.

Related Articles

Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate to severe plaque psoriasis.

J Dermatolog Treat. 2018 Apr 20;:1-20

Authors: Romero-Jimenez RM, Escudero-Vilaplana V, Baniandres Rodriguez O, García Martín E, Mateos Mayo A, Sanjurjo Saez M

Abstract
PURPOSE: The aim of this study was to identify clinical factors associated with dose reduction and dose escalation in the treatment with ustekinumab in patients with moderate to severe plaque psoriasis.
MATERIALS AND METHODS: An observational, longitudinal and retrospective study was conducted using patients with moderate to severe plaque psoriasis. We reviewed clinical histories and variables were recorded on a database (patients' characteristics, pharmacotherapeutics, effectiveness and safety). We evaluated correlation between dose reduction, dose escalation and used dose with other variables.
RESULTS: Of the study's 62 patients, Ustekinumab dose was adjusted in 45.2% (22.6% with reduced doses and 22.6% with increased doses). We found a statistically significant correlation between extending the dosing interval and the absence of psoriatic arthritis, no concomitant systemic therapies, treatment time with ustekinumab, lower PASI at week 28 and achieving PASI75 at week 28. There was also a statistically significant correlation between dose escalation and diabetes mellitus, psoriatic arthritis, prior biological treatments, concomitant systemic therapies, concomitant phototherapy and not achieving PASI75 at week 28.
CONCLUSIONS: Dose reduction strategies would increase ustekinumab efficiency in patients that achieve PASI 75 without psoriatic arthritis, diabetes mellitus, previous BT and concomitant treatment with conventional systemic drugs.

PMID: 29676189 [PubMed - as supplied by publisher]

https://ift.tt/2HlCLiE